Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models

Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models

Abstract Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose conventionally fractionated) radio-therapy. Emerging evidence suggests that pancreatic stellate cells (PSCs) secrete deoxycytidine, which confers resistance to gemcitabine. In particular, deoxy...

Full description

Bibliographic Details
Main Authors: Pei Pei Che, Alessandro Gregori, Omidreza Firuzi, Max Dahele, Peter Sminia, Godefridus J. Peters, Elisa Giovannetti
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Experimental Hematology & Oncology
Subjects:
Pancreatic cancer
Therapy resistance
Stellate cells
Deoxycytidine
Online Access:http://link.springer.com/article/10.1186/s40164-020-00176-0

Internet

http://link.springer.com/article/10.1186/s40164-020-00176-0

Similar Items